The lack of effect of therapeutic vaccination with a pre-S2/S HBV vaccine in the immune tolerant phase of chronic HBV infection

Journal of Clinical Gastroenterology

Volumn 37, Issue 4, 2003, Pages 330-335

  Yalcin, Kendal ^a   Danis, Ramazan ^a   Degertekin, Halil ^a   Alp, M Nail ^a   Tekes, Selahattin ^a   Budak, Turgay ^a  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Hepatitis B virus; Immune tolerance, HBeAg; Recombinant hepatitis B vaccine; Specific immunotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LIVER BIOPSY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; VACCINATION; VIRUS REPLICATION;

ADOLESCENT; ADULT; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNE TOLERANCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; TREATMENT OUTCOME; TURKEY;

EID: 0141455257     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200310000-00012     Document Type: Article

References (33)

1. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733-1745.
2. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med. 1997;336:1855-1859.
3. Chang MH, Hsu HY, Hsu HC, et al. The significance of spontaneous hepatitis e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis e antigen before 3 years of age. Hepatology. 1995;22:1387-1392.
4. Lok AS, Lai CL, Wu PC, et al. Spontaneous hepatitis e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology. 1987;92:1839-1843.
5. Wong DKH, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med. 1993;119:312-323.
6. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;333:1657-1661.
7. Mancini M, Hadchouel M, Tiollais P, et al. Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumventing "nonresponse" to HBsAg. J Med Virol. 1993;39:67-74.
8. Couillin I, Pol S, Mancini M, et al. Specific vaccine therapy in chronic hepatitis B: Induction of T cell proliferative responses specific for envelope antigens. J Infect Dis. 1999;180:15-26.
9. Pol S, Driss F, Michel ML, et al. Specific vaccine therapy in chronic hepatitis B infection [letter]. Lancet. 1994;344:2.
10. Wen YM, Wu XH, Hu DC, et al. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy [letter]. Lancet. 1995;345:1575-1576.
11. Pol S. Immunotherapy of chronic hepatitis B by anti HBV vaccine. Biomed Pharmacother. 1995;49:105-109.
12. Pol S, Driss F, Carnot F, et al. Efficacy of immunotherapy with vaccination against hepatitis B virus: on virus B multiplication. C R Acad Sci III. 1993;316:688-691.
13. Horiike N, Akbar SF, Ninomiya T, et al. Activation and maturation of antigen-presenting dendritic cells during vaccine therapy in patients with chronic hepatitis due to hepatitis B virus. Hepatol Res. 2002;23:38-47.
14. Pol S, Nalpas B, Driss F, et al. Multicenter study group: efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol. 2001;34:917-921.
15. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-435.
16. Kakimi K, Isogawa M, Chung J, et al. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J Virol. 2002;76:8609-8620.
17. Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology. 1988;8:1130-1133.
18. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat. 2002;9:52-61.
19. Yalcin K, Degertekin H, Alp MN, et al. Serum HBV DNA levels in chronic hepatitis B patients in Southeastern Turkey. Turk J Gastroenterol. 2000;11(suppl):1-90A.
20. Lai CL, Ching K, Tung AK, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology. 1997;25:241-244.
21. Zoulim F, Trepo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol. 1998;29:151-168.
22. Lok AS, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology. 1992;102:2091-2097.
23. Mancini M, Hadchouel M, Tiollais P, et al. Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumventing "nonresponse" to HBsAg. J Med Virol. 1993;39:67-74.
24. Couillin I, Pol S, Mancini M, et al. Specific vaccine therapy in chronic hepatitis B: Induction of T cell proliferative responses specific for envelope antigens. J Infect Dis. 1999;180:15-26.
25. Akbar SM, Abe M, Masumoto T, et al. Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells. J Hepatol. 1999;30:755-764.
26. Akbar SM, Kajino K, Tanimoto K, et al. Placebo controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice. J Hepatol. 1997;26:131-137.
27. Bozdayi AM, Bozkaya H, Turkyilmaz A, et al. Polymorphism of precore region of hepatitis B virus DNA among patients with chronic HBV infection in Turkey. Infection. 1999;27:357-360.
28. Hervas-Stubbs S, Lasarte JJ, Sarobe P, et al. Therapeutic vaccination of woodchucks hepatitis virus infection. J Hepatol. 1997;27:726-737.
29. Heintges T, Petry W, Kaldewey M, et al. Combination therapy of active HBsAg vaccination and interferon-alpha in interferon-alpha nonresponders with chronic hepatitis B. Dig Dis Sci. 2001;46:901-906.
30. Senturk H, Tabak F, Akdogan M, et al. Therapeutic vaccination in chronic hepatitis B. J Gastroenterol Hepatol. 2002;7:72-76.
31. Hervas-Stubbs S, Lasarte JJ, Sarobe P, et al. T-helper cell response to woodchuck hepatitis virus antigens after therapeutics vaccination of chronically-infected animals treated with lamivudine. J Hepatol. 2001;35:105-111.
32. Dahmen A, Herzog-Hauff S, Bocher WO, et al. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol. 2002;66:452-460.
33. Yap SP, Sulaiman A, Lesmana L, et al. Immunotherapy of chronic hepatitis B in Asian patients using a novel triple antigen hepatitis B vaccine (Hepacare). Antiviral Ther. 2000;5:B68.